Tumor-tumor interaction correlated with prolonged OS following EGFR TKI therapy (lower risk score; per 10%, HR = 0.73, 95% CI 0.58–0.90, P = 0.004), while tumor-stroma interaction negatively correlated with OS (higher risk score; per 10%, HR = 1.53, 95% CI 1.11–2.10, P = 0.009). Here, EGFR is linked to neoplasm.